Toshiharu Motokubota

Title: **Innovative Contributions of Toshiharu Motokubota in Biopharmaceuticals**

Introduction

Toshiharu Motokubota, an accomplished inventor based in Arcadia, CA, has made significant contributions to the field of biopharmaceuticals. With a total of four patents to his name, Motokubota's work primarily focuses on the purification and viral inactivation of critical blood proteins, particularly Factor VIII, which is essential in treating bleeding disorders like hemophilia.

Latest Patents

Motokubota's most recent patents showcase his innovative approaches to enhancing the safety and efficacy of Factor VIII. One such patent details a **Process for Viral Inactivation of Lyophilized Blood Proteins**. This process entails forming a stable complex between Factor VIII and cyclodextrin in an aqueous solution, which is subsequently lyophilized. The resulting complex is then heated to 60°C to effectively inactivate any viral contaminants, ensuring the safety of the blood-derived product prior to administration to patients.

In addition, he has developed an **Anion Exchange Process for the Purification of Factor VIII**. This inventive method involves the dissolution of cryoprecipitate in a heparin solution, followed by polyethylene glycol precipitation for initial purification. The Factor VIII complex is then isolated using an anion exchange column and eluted with a calcium chloride buffer. The final product is further stabilized and reconstituted, making it ready for therapeutic use.

Career Highlights

Motokubota's career at Alpha Therapeutic Corporation has been marked by his dedication to advancing biopharmaceutical technologies. His innovative discoveries have contributed not only to the purification processes but also to the overall understanding of Factor VIII's applications in clinical therapies. These advancements are vital for improving treatment outcomes for patients with clotting disorders.

Collaborations

Throughout his career, Motokubota has collaborated with professionals like Prabir Bhattacharya and Norman M. Fedalizo. Their joint efforts have fostered a collaborative environment that has spurred significant advancements in the purification and viral inactivation processes of blood proteins.

Conclusion

Toshiharu Motokubota stands out as a prominent inventor in the biopharmaceutical field, particularly known for his patents related to Factor VIII. His innovative techniques not only enhance the safety of blood products but also provide critical therapeutic solutions for individuals suffering from hemophilia. As the biopharmaceutical landscape continues to evolve, the contributions of inventors like Motokubota are vital for driving progress and improving patient care.